UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
April 10, 2012 (April 4, 2012)
Date of Report (date of earliest event reported)
TRANSCEPT PHARMACEUTICALS, INC.
(Exact name of Registrant as specified in its charter)
| | | | |
| Delaware | | 000-51967 | | 33-0960223 |
(State or other jurisdiction of incorporation or organization) | | (Commission File Number) | | (I.R.S. Employer Identification Number) |
1003 W. Cutting Blvd., Suite #110
Point Richmond,
California 94804
(Address of principal executive offices)
(510) 215-3500
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| ITEM 5.02. | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
Transcept Pharmaceuticals, Inc. (“Transcept”) has promoted Thomas P. Soloway, Transcept’s current Senior Vice President, Operations and Chief Financial Officer, to the position of Executive Vice President and Chief Operating Officer, effective as of April 4, 2012. Mr. Soloway will continue to serve as Transcept’s Chief Financial Officer until such time as a successor is appointed.
Mr. Soloway will also assume the role of principal accounting officer effective upon the resignation of Marilyn E. Wortzman, Transcept’s current Vice President, Finance and principal accounting officer. Ms. Wortzman’s resignation is expected to be effective on or about April 30, 2012.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | | | |
| | | | TRANSCEPT PHARMACEUTICALS, INC. |
| | | |
Date: April 10, 2012 | | | | | | |
| | | | By: | | /s/ Marilyn E. Wortzman |
| | | | | | Name: Marilyn E. Wortzman |
| | | | | | Title: Vice President, Finance |
